pcDNA™3.1/Zeo (+) Mammalian Expression Vector
Product Image
Invitrogen™

pcDNA™3.1/Zeo (+) Mammalian Expression Vector

このpcDNA™3.1/Zeo(+)ベクターは、さまざまな哺乳類細胞株における高レベルでの構成的発現のために設計されています。Geneticin™選択可能マーカーおよび逆方向の複数のクローニング部位を含みます。pcDNA™3.1発現ベクターファミリーpcDNA™3.1の3つのタグなしバージョン(個別に使用可能)には、それぞれに異なる選択可能マーカー(Geneticin™、ゼオシン™、またはHygromycin詳細を見る
製品番号(カタログ番号)数量
V8602020 μg
製品番号(カタログ番号) V86020
価格(JPY)
78,600
Online offer
Ends: 27-Mar-2026
112,300
割引額 33,700 (30%)
20 µg
お問い合わせください ›
数量:
20 μg
このpcDNA™3.1/Zeo(+)ベクターは、さまざまな哺乳類細胞株における高レベルでの構成的発現のために設計されています。Geneticin™選択可能マーカーおよび逆方向の複数のクローニング部位を含みます。

pcDNA™3.1発現ベクターファミリー
pcDNA™3.1の3つのタグなしバージョン(個別に使用可能)には、それぞれに異なる選択可能マーカー(Geneticin™、ゼオシン™、またはHygromycin)があり、単独で使用することも、相互コトランスフェクションで使用することもできます。3つのベクターは以下の特長を備えています:
•高レベル発現用のサイトメガロウイルス(CMV)エンハンサープロモーター
• フォワード(+)方向の大規模な複数のクローニング部位
• ウシ成長ホルモン(BGH)ポリアデニル化シグナルおよびmRNA安定性向上のための転写終了配列
• ラージT抗原(COS-1やCOS-7など)を発現する細胞株内でのエピソーム複製および単純なベクターレスキュー用のSV40起源
• アンピシリン耐性遺伝子および大腸菌の選択および維持のためのpUC起源
研究用にのみ使用できます。診断用には使用いただけません。
仕様
構成または誘導システム構造的
供給タイプTransfection
使用対象(アプリケーション)構成的発現
製品タイプ哺乳類発現用ベクター
数量20 μg
選択剤(真核生物)ゼオシン™
ベクターpcDNA
クローニング法制限酵素/MCS
製品ラインpcDNA
プロモーターCMV
タンパク質タグタグなし
Unit Size20 µg
組成および保存条件
20 µgのこのpcDNA™3.1/Zeo(+)ベクターと発現コントロールが、超らせん型で凍結乾燥された状態で提供されます。-20℃で保存ベクターは、適切に保存されている場合、6カ月間安定していることが保証されます。

よくあるご質問(FAQ)

I performed stable selection but my antibiotic-resistant clones do not express my gene of interest. What could have gone wrong?

Here are possible causes and solutions:

Detection method may not be appropriate or sensitive enough:
- We recommend optimizing the detection protocol or finding more sensitive methods. If the protein is being detected by Coomassie/silver staining, we recommend doing a western blot for increased sensitivity. The presence of endogenous proteins in the lysate may obscure the protein of interest in a Coomassie/silver stain. If available, we recommend using a positive control for the western blot.
- Insufficient number of clones screened: Screen at least 20 clones.
- Inappropriate antibiotic concentration used for stable selection: Make sure the antibiotic kill curve was performed correctly. Since the potency of a given antibiotic depends upon cell type, serum, medium, and culture technique, the dose must be determined each time a stable selection is performed. Even the stable cell lines we offer may be more or less sensitive to the dose we recommend if the medium or serum is significantly different.
- Expression of gene product (even low level) may not be compatible with growth of the cell line: Use an inducible expression system.
- Negative clones may result from preferential linearization at a vector site critical for expression of the gene of interest: Linearize the vector at a site that is not critical for expression, such as within the bacterial resistance marker.

I used a mammalian expression vector but do not get any expression of my protein. Can you help me troubleshoot?

Here are possible causes and solutions:

- Try the control expression that is included in the kit
Possible detection problem:

- Detection of expressed protein may not be possible in a transient transfection, since the transfection efficiency may be too low for detection by methods that assess the entire transfected population. We recommend optimizing the transfection efficiency, doing stable selection, or using methods that permit examination of individual cells. You can also increase the level of expression by changing the promoter or cell type.
- Expression within the cell may be too low for the chosen detection method. We recommend optimizing the detection protocol or finding more sensitive methods. If the protein is being detected by Coomassie/silver staining, we recommend doing a western blot for increased sensitivity. The presence of endogenous proteins in the lysate may obscure the protein of interest in a Coomassie/silver stain. If available, we recommend using a positive control for the western blot. Protein might be degraded or truncated: Check on a Northern. Possible time-course issue: Since the expression of a protein over time will depend upon the nature of the protein, we always recommend doing a time course for expression. A pilot time-course assay will help to determine the optimal window for expression. Possible cloning issues: Verify clones by restriction digestion and/or sequencing.

Find additional tips, troubleshooting help, and resources within our Protein Expression Support Center.

I am using a mammalian expression vector that has the neomycin resistance gene. Can I use neomycin for stable selection in mammalian cells?

No; neomycin is toxic to mammalian cells. We recommend using Geneticin (a.k.a. G418 Sulfate), as it is a less toxic and very effective alternative for selection in mammalian cells.

Is it okay if my construct has an ATG that is upstream of the ATG in my gene of interest? Will it interfere with translation of my gene?

Translation initiation will occur at the first ATG encountered by the ribosome, although in the absence of a Kozak sequence, initiation will be relatively weak. Any insert downstream would express a fusion protein if it is in frame with this initial ATG, but levels of expressed protein are predicted to be low if there is a non-Kozak consensus sequence. If the vector contains a non-Kozak consensus ATG, we recommend that you clone your gene upstream of that ATG and include a Kozak sequence for optimal expression.

What is the difference between pcDNA3.1 vectors and the pcDNA3.3-TOPO vector?

pcDNA3.1 vectors contain the core CMV promoter that is truncated before the start of transcription, whereas the pcDNA 3.3-TOPO vector has the 672 bp native CMV promoter. This native CMV promoter allows high-level gene expression with two- to five-fold higher protein yields compared to other expression vectors. pcDNA3.1 vectors are available in restriction, TOPO, and Gateway cloning versions and as untagged and epitope-tagged versions, whereas the pcDNA3.3-TOPO vector is a TOPO TA-adapted, untagged vector that can be used to express native proteins without extraneous amino acids, and is hence ideal for antibody production and structural biology.

引用および参考文献 (19)

引用および参考文献
Abstract
A novel N-terminal splice variant of the rat H+-K+-ATPase alpha2 subunit. Cloning, functional expression, and renal adaptive response to chronic hypokalemia.
Authors:Kone BC, Higham SC
Journal:J Biol Chem
PubMed ID:9446555
'The H+-K+-ATPase of renal collecting duct mediates K+ conservation during chronic hypokalemia. K+ deprivation promotes H+-K+-ATPase alpha2 (HKalpha2) gene expression in the medullary collecting duct, the principal site of active K+ reabsorption, suggesting that this isozyme contributes to renal K+ reclamation. We report here that alternative transcriptional initiation and mRNA ... More
An alternative processing of integrin alpha(v) subunit in tumor cells by membrane type-1 matrix metalloproteinase.
Authors: Ratnikov Boris I; Rozanov Dmitri V; Postnova Tanya I; Baciu Peter G; Zhang Heying; DiScipio Richard G; Chestukhina Galina G; Smith Jeffrey W; Deryugina Elena I; Strongin Alex Y;
Journal:J Biol Chem
PubMed ID:11741954
'Membrane type-1 matrix metalloproteinase (MT1-MMP) and alpha(v)beta(3) integrin are both essential to cell invasion. Maturation of integrin pro-alpha(v)chain (pro-alpha(v)) involves its cleavage by proprotein convertases (PC) to form the disulfide-bonded 125-kDa heavy and 25-kDa light alpha chains. Our report presents evidence of an alternative pathway of pro-alpha(v) processing involving MT1-MMP. ... More
Apical sorting of beta-secretase limits amyloid beta-peptide production.
Authors: Capell Anja; Meyn Liane; Fluhrer Regina; Teplow David B; Walter Jochen; Haass Christian;
Journal:J Biol Chem
PubMed ID:11741885
'Polarized cells such as neurons and endothelial cells appear to be involved in two invariant pathological features of Alzheimer''s disease pathology, namely the formation of senile plaques and cerebral amyloid angiopathy. This implicates polarized sorting mechanisms in the production and accumulation of amyloid beta-peptide (Abeta). We have now studied polarized ... More
Cellular response to oncogenic ras involves induction of the Cdk4 and Cdk6 inhibitor p15(INK4b).
Authors:Malumbres M, Perez De Castro I, Hernandez MI, Jimenez M, Corral T, Pellicer A
Journal:Mol Cell Biol
PubMed ID:10733595
'The cell cycle inhibitor p15(INK4b) is frequently inactivated by homozygous deletion together with p16(INK4a) and p19(ARF) in some types of tumors. Although the tumor suppressor capability of p15(INK4b) is still questioned, it has been found to be specifically inactivated by hypermethylation in hematopoietic malignancies in the absence of p16(INK4a) alterations. ... More
Insulin-degrading enzyme rapidly removes the beta-amyloid precursor protein intracellular domain (AICD).
Authors: Edbauer Dieter; Willem Michael; Lammich Sven; Steiner Harald; Haass Christian;
Journal:J Biol Chem
PubMed ID:11809755
'The intramembranous gamma-secretase cleavage of the beta-amyloid precursor protein (APP) is dependent on biologically active presenilins (PS). Notch also undergoes a similar PS-dependent gamma-secretase-like cleavage, resulting in the liberation of the Notch intracellular domain (NICD), which is critically required for developmental signal transduction. gamma-Secretase processing of APP results in the ... More